Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 887 entries
Sorted by: Best Match Show Resources per page
HBV Core Protein Enhances Cytokine Production.

Diseases (Basel, Switzerland)

Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O.
PMID: 28943621
Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213.

Hepatitis B virus (HBV) infection, a cause of hepatocellular carcinoma (HCC), remains a serious global health concern. HCC development and human hepatocarcinogenesis are associated with hepatic inflammation caused by host interferons and cytokines. This article focused on the association...

Cite
Kanda T, Wu S, Sasaki R, et al. HBV Core Protein Enhances Cytokine Production. Diseases. 2015;3(3):213-220doi: 10.3390/diseases3030213.
Kanda, T., Wu, S., Sasaki, R., Nakamura, M., Haga, Y., Jiang, X., Nakamoto, S., & Yokosuka, O. (2015). HBV Core Protein Enhances Cytokine Production. Diseases (Basel, Switzerland), 3(3), 213-220. https://doi.org/10.3390/diseases3030213
Kanda, Tatsuo, et al. "HBV Core Protein Enhances Cytokine Production." Diseases (Basel, Switzerland) vol. 3,3 (2015): 213-220. doi: https://doi.org/10.3390/diseases3030213
Kanda T, Wu S, Sasaki R, Nakamura M, Haga Y, Jiang X, Nakamoto S, Yokosuka O. HBV Core Protein Enhances Cytokine Production. Diseases. 2015 Sep 17;3(3):213-220. doi: 10.3390/diseases3030213. PMID: 28943621; PMCID: PMC5548245.
Copy Download .nbib Format: NLM
Critical Involvement of Environmental Carbon Dioxide Fixation to Drive Wax Ester Fermentation in Euglena.

PloS one

Padermshoke A, Ogawa T, Nishio K, Nakazawa M, Nakamoto M, Okazawa A, Kanaya S, Arita M, Ohta D.
PMID: 27669566
PLoS One. 2016 Sep 26;11(9):e0162827. doi: 10.1371/journal.pone.0162827. eCollection 2016.

Accumulation profiles of wax esters in Euglena gracilis Z were studied under several environmental conditions. The highest amount of total wax esters accumulated under hypoxia in the dark, and C28 (myristyl-myristate, C14:0-C14:0) was prevalent among all conditions investigated. The...

Cite
Padermshoke A, Ogawa T, Nishio K, et al. Critical Involvement of Environmental Carbon Dioxide Fixation to Drive Wax Ester Fermentation in Euglena. PLoS One. 2016;11(9):e0162827doi: 10.1371/journal.pone.0162827.
Padermshoke, A., Ogawa, T., Nishio, K., Nakazawa, M., Nakamoto, M., Okazawa, A., Kanaya, S., Arita, M., & Ohta, D. (2016). Critical Involvement of Environmental Carbon Dioxide Fixation to Drive Wax Ester Fermentation in Euglena. PloS one, 11(9), e0162827. https://doi.org/10.1371/journal.pone.0162827
Padermshoke, Adchara, et al. "Critical Involvement of Environmental Carbon Dioxide Fixation to Drive Wax Ester Fermentation in Euglena." PloS one vol. 11,9 (2016): e0162827. doi: https://doi.org/10.1371/journal.pone.0162827
Padermshoke A, Ogawa T, Nishio K, Nakazawa M, Nakamoto M, Okazawa A, Kanaya S, Arita M, Ohta D. Critical Involvement of Environmental Carbon Dioxide Fixation to Drive Wax Ester Fermentation in Euglena. PLoS One. 2016 Sep 26;11(9):e0162827. doi: 10.1371/journal.pone.0162827. eCollection 2016. PMID: 27669566; PMCID: PMC5036851.
Copy Download .nbib Format: NLM
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.

Biology

Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O.
PMID: 28486403
Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030.

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated...

Cite
Kanda T, Nakamura M, Yasui S, et al. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6(2)doi: 10.3390/biology6020030.
Kanda, T., Nakamura, M., Yasui, S., Haga, Y., Tawada, A., Suzuki, E., Ooka, Y., Takahashi, K., Sasaki, R., Wu, S., Nakamoto, S., Arai, M., Imazeki, F., & Yokosuka, O. (2017). Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology, 6(2), . https://doi.org/10.3390/biology6020030
Kanda, Tatsuo, et al. "Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin." Biology vol. 6,2 (2017). doi: https://doi.org/10.3390/biology6020030
Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030. PMID: 28486403; PMCID: PMC5485477.
Copy Download .nbib Format: NLM
Degradation of Dithiocarbamate Fungicide Polycarbamate in Upland Soils.

Bioscience, biotechnology, and biochemistry

Kumagai H, Nakamoto K, Nakamura M, Hirose S, Ichikawa Y, Endo J, Ikari H.
PMID: 27286221
Biosci Biotechnol Biochem. 1992 Jan;56(5):828-30. doi: 10.1271/bbb.56.828.

No abstract available.

Cite
Kumagai H, Nakamoto K, Nakamura M, et al. Degradation of Dithiocarbamate Fungicide Polycarbamate in Upland Soils. Biosci Biotechnol Biochem. 1992;56(5):828-30doi: 10.1271/bbb.56.828.
Kumagai, H., Nakamoto, K., Nakamura, M., Hirose, S., Ichikawa, Y., Endo, J., & Ikari, H. (1992). Degradation of Dithiocarbamate Fungicide Polycarbamate in Upland Soils. Bioscience, biotechnology, and biochemistry, 56(5), 828-30. https://doi.org/10.1271/bbb.56.828
Kumagai, H, et al. "Degradation of Dithiocarbamate Fungicide Polycarbamate in Upland Soils." Bioscience, biotechnology, and biochemistry vol. 56,5 (1992): 828-30. doi: https://doi.org/10.1271/bbb.56.828
Kumagai H, Nakamoto K, Nakamura M, Hirose S, Ichikawa Y, Endo J, Ikari H. Degradation of Dithiocarbamate Fungicide Polycarbamate in Upland Soils. Biosci Biotechnol Biochem. 1992 Jan;56(5):828-30. doi: 10.1271/bbb.56.828. PMID: 27286221.
Copy Download .nbib Format: NLM
Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient.

Clinical journal of gastroenterology

Kanda T, Nakamoto S, Arai M, Miyamura T, Wu S, Fujiwara K, Yokosuka O.
PMID: 26181455
Clin J Gastroenterol. 2013 Apr;6(2):160-3. doi: 10.1007/s12328-013-0366-1. Epub 2013 Feb 17.

We describe a patient infected with hepatitis C virus (HCV) genotype 1 who failed to respond to interferon with or without ribavirin seven times but who then achieved sustained virological response by the combination of interferon-beta plus ribavirin treatment...

Cite
Kanda T, Nakamoto S, Arai M, et al. Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clin J Gastroenterol. 2013;6(2):160-3doi: 10.1007/s12328-013-0366-1.
Kanda, T., Nakamoto, S., Arai, M., Miyamura, T., Wu, S., Fujiwara, K., & Yokosuka, O. (2013). Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clinical journal of gastroenterology, 6(2), 160-3. https://doi.org/10.1007/s12328-013-0366-1
Kanda, Tatsuo, et al. "Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient." Clinical journal of gastroenterology vol. 6,2 (2013): 160-3. doi: https://doi.org/10.1007/s12328-013-0366-1
Kanda T, Nakamoto S, Arai M, Miyamura T, Wu S, Fujiwara K, Yokosuka O. Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clin J Gastroenterol. 2013 Apr;6(2):160-3. doi: 10.1007/s12328-013-0366-1. Epub 2013 Feb 17. PMID: 26181455.
Copy Download .nbib Format: NLM
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Oncotarget

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.
PMID: 29545925
Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

BACKGROUND: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV...

Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy Download .nbib Format: NLM
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.

Case reports in gastroenterology

Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O.
PMID: 27721720
Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016.

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was...

Cite
Sasaki R, Kanda T, Ohtsuka M, et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016;10(2):366-372doi: 10.1159/000447423.
Sasaki, R., Kanda, T., Ohtsuka, M., Yasui, S., Haga, Y., Nakamura, M., Yokoyama, M., Wu, S., Nakamoto, S., Arai, M., Maruyama, H., Miyazaki, M., & Yokosuka, O. (2016). Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case reports in gastroenterology, 10(2), 366-372. https://doi.org/10.1159/000447423
Sasaki, Reina, et al. "Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin." Case reports in gastroenterology vol. 10,2 (2016): 366-372. doi: https://doi.org/10.1159/000447423
Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016. PMID: 27721720; PMCID: PMC5043295.
Copy Download .nbib Format: NLM
Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.

World journal of hepatology

Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O.
PMID: 26052401
World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125.

Chronic hepatitis C virus (HCV) infection can cause liver cirrhosis and hepatocellular carcinoma (HCC). Several studies have demonstrated that the eradication of HCV reduces the occurrence of HCC. In Japan, as many people live to an advanced age, HCV-infected...

Cite
Sasaki R, Kanda T, Nakamoto S, et al. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015;7(8):1125-32doi: 10.4254/wjh.v7.i8.1125.
Sasaki, R., Kanda, T., Nakamoto, S., Haga, Y., Nakamura, M., Yasui, S., Jiang, X., Wu, S., Arai, M., & Yokosuka, O. (2015). Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World journal of hepatology, 7(8), 1125-32. https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki, Reina, et al. "Natural interferon-beta treatment for patients with chronic hepatitis C in Japan." World journal of hepatology vol. 7,8 (2015): 1125-32. doi: https://doi.org/10.4254/wjh.v7.i8.1125
Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol. 2015 May 18;7(8):1125-32. doi: 10.4254/wjh.v7.i8.1125. PMID: 26052401; PMCID: PMC4450189.
Copy Download .nbib Format: NLM
Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias.

Neurology research international

Dalrymple K, Saito EK, Diaz N, Morrow J, Nakamoto B, McMurtray AM.
PMID: 25574388
Neurol Res Int. 2014;2014:423602. doi: 10.1155/2014/423602. Epub 2014 Dec 10.

Background. Patients with progressive dementing disorders associated with cortical cholinergic dysfunction gradually develop cholinergic deficits many years before symptom onset and may begin to smoke cigarettes during midlife as a form of self-medication. The aim of this study was...

Cite
Dalrymple K, Saito EK, Diaz N, et al. Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias. Neurol Res Int. 2014;2014:423602doi: 10.1155/2014/423602.
Dalrymple, K., Saito, E. K., Diaz, N., Morrow, J., Nakamoto, B., & McMurtray, A. M. (2014). Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias. Neurology research international, 2014423602. https://doi.org/10.1155/2014/423602
Dalrymple, Kyle, et al. "Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias." Neurology research international vol. 2014 (2014): 423602. doi: https://doi.org/10.1155/2014/423602
Dalrymple K, Saito EK, Diaz N, Morrow J, Nakamoto B, McMurtray AM. Past Cigarette Smoking Is More Common among Those with Cholinergic Than Noncholinergic Dementias. Neurol Res Int. 2014;2014:423602. doi: 10.1155/2014/423602. Epub 2014 Dec 10. PMID: 25574388; PMCID: PMC4276668.
Copy Download .nbib Format: NLM
Acute liver injury in a patient with alcohol dependence: a case resembling autoimmune hepatitis or drug-induced liver injury.

Case reports in gastroenterology

Hayashi M, Kanda T, Nakamura M, Miyamura T, Yasui S, Nakamoto S, Wu S, Arai M, Imazeki F, Yokosuka O.
PMID: 24847195
Case Rep Gastroenterol. 2014 Apr 05;8(1):129-33. doi: 10.1159/000362442. eCollection 2014 Jan.

Some patients with alcohol dependence may initially present with atypical laboratory and histological features resembling autoimmune hepatitis (AIH) or drug-induced liver injury (DILI). Even with liver biopsy, it may be difficult to diagnose certain patients with alcohol dependence. However,...

Cite
Hayashi M, Kanda T, Nakamura M, et al. Acute liver injury in a patient with alcohol dependence: a case resembling autoimmune hepatitis or drug-induced liver injury. Case Rep Gastroenterol. 2014;8(1):129-33doi: 10.1159/000362442.
Hayashi, M., Kanda, T., Nakamura, M., Miyamura, T., Yasui, S., Nakamoto, S., Wu, S., Arai, M., Imazeki, F., & Yokosuka, O. (2014). Acute liver injury in a patient with alcohol dependence: a case resembling autoimmune hepatitis or drug-induced liver injury. Case reports in gastroenterology, 8(1), 129-33. https://doi.org/10.1159/000362442
Hayashi, Masahiro, et al. "Acute liver injury in a patient with alcohol dependence: a case resembling autoimmune hepatitis or drug-induced liver injury." Case reports in gastroenterology vol. 8,1 (2014): 129-33. doi: https://doi.org/10.1159/000362442
Hayashi M, Kanda T, Nakamura M, Miyamura T, Yasui S, Nakamoto S, Wu S, Arai M, Imazeki F, Yokosuka O. Acute liver injury in a patient with alcohol dependence: a case resembling autoimmune hepatitis or drug-induced liver injury. Case Rep Gastroenterol. 2014 Apr 05;8(1):129-33. doi: 10.1159/000362442. eCollection 2014 Jan. PMID: 24847195; PMCID: PMC4025146.
Copy Download .nbib Format: NLM
Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation.

Hepatology research : the official journal of the Japan Society of Hepatology

Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, Nakamoto N, Hibi T, Yagi H, Abe Y, Matsubara K, Chu PS, Wakayama Y, Taniki N, Yamaguchi A, Amemiya R, Miyake R, Mizota T, Kanai T, Kitagawa Y.
PMID: 26854748
Hepatol Res. 2016 Oct;46(11):1118-1128. doi: 10.1111/hepr.12666. Epub 2016 Apr 22.

AIM: Simeprevir (SMV) is a protease inhibitor which demonstrates good tolerability and high antiviral response in patients with hepatitis C. The clinical outcomes of triple therapy using simeprevir, pegylated interferon and ribavirin (SMV/PEG IFN/RBV) for recurrent hepatitis C after...

Cite
Shinoda M, Ebinuma H, Itano O, et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2016;46(11):1118-1128doi: 10.1111/hepr.12666.
Shinoda, M., Ebinuma, H., Itano, O., Yamagishi, Y., Obara, H., Kitago, M., Nakamoto, N., Hibi, T., Yagi, H., Abe, Y., Matsubara, K., Chu, P. S., Wakayama, Y., Taniki, N., Yamaguchi, A., Amemiya, R., Miyake, R., Mizota, T., Kanai, T., & Kitagawa, Y. (2016). Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatology research : the official journal of the Japan Society of Hepatology, 46(11), 1118-1128. https://doi.org/10.1111/hepr.12666
Shinoda, Masahiro, et al. "Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,11 (2016): 1118-1128. doi: https://doi.org/10.1111/hepr.12666
Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, Nakamoto N, Hibi T, Yagi H, Abe Y, Matsubara K, Chu PS, Wakayama Y, Taniki N, Yamaguchi A, Amemiya R, Miyake R, Mizota T, Kanai T, Kitagawa Y. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2016 Oct;46(11):1118-1128. doi: 10.1111/hepr.12666. Epub 2016 Apr 22. PMID: 26854748.
Copy Download .nbib Format: NLM
Effective localization in tumor-induced osteomalacia using .

Endocrinology, diabetes & metabolism case reports

Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, Warigaya K, Nakamoto Y, Akamizu T.
PMID: 28469928
Endocrinol Diabetes Metab Case Rep. 2017 Apr 19;2017. doi: 10.1530/EDM-17-0005. eCollection 2017.

SUMMARY: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by renal phosphate wasting leading to hypophosphatemia due to excessive actions of fibroblast growth factor 23 (FGF23) produced by the tumors. Although the best way of curing TIO is...

Cite
Kawai S, Ariyasu H, Furukawa Y, et al. Effective localization in tumor-induced osteomalacia using . Endocrinol Diabetes Metab Case Rep. 2017;2017doi: 10.1530/EDM-17-0005.
Kawai, S., Ariyasu, H., Furukawa, Y., Yamamoto, R., Uraki, S., Takeshima, K., Warigaya, K., Nakamoto, Y., & Akamizu, T. (2017). Effective localization in tumor-induced osteomalacia using . Endocrinology, diabetes & metabolism case reports, 2017. https://doi.org/10.1530/EDM-17-0005
Kawai, Shintaro, et al. "Effective localization in tumor-induced osteomalacia using ." Endocrinology, diabetes & metabolism case reports vol. 2017 (2017). doi: https://doi.org/10.1530/EDM-17-0005
Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, Warigaya K, Nakamoto Y, Akamizu T. Effective localization in tumor-induced osteomalacia using . Endocrinol Diabetes Metab Case Rep. 2017 Apr 19;2017. doi: 10.1530/EDM-17-0005. eCollection 2017. PMID: 28469928; PMCID: PMC5409940.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 887 entries